プロフィール詳細

プロジェクトを作成

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Dr. Stavroula L.に依頼

Cyprus

Biochemist & Molecular Biologist | Research, Data Analysis & Scientific/Grant Writing Support

プロフィール概要

Stavroula Louka is a Biochemist and Molecular Biologist with experience in genomics, biobanking, biomarker discovery, and rare disease research. She has authored peer-reviewed publications in high-impact journals, including Nature Communications and Communications Biology, and has collaborated with both academic and industry partners. Beyond her scientific expertise, she has substantial experience in technical and academic writing, literature reviews, report preparation, and copy-editing. She has been actively involved in grant and proposal writing (EU programmes, tenders, and national calls) and has a proven track record in supporting successful funding applications. She is also trained in Good Clinical Practice (GCP), Good Clinical Laboratory Practice (GCLP), bioethics, and research integrity, ensuring compliance with international standards in biomedical research. Her interdisciplinary background allows her to deliver high-quality support in research design, data analysis, manuscript preparation, and proposal development.

専門分野

• ☆ Computational Biology
• ☆ Biostatistics
• ☆ Biochemistry
• ☆ Immunoassay
• ☆ Biochemical Assays
• ☆ Structural Biology
• ☆ Enzyme Activity Assays
• ☆ Binding Assays
• ☆ Molecular Biology
• ☆ Biomarkers
• ☆ Genetics
• ☆ Biomarker Discovery
• ☆ Clinical Trials
• ☆ Patient Recruitment
• ☆ Clinical Data Management
• ☆ Clinical Trial Site Selection & Monitoring
• ☆ Clinical Trials Data Analysis
• ☆ Medical Genetics
• ☆ Immunogenetics
• ☆ Human Biology
• ☆ Clinical Laboratory Science
• ☆ Clinical Biochemistry
• ☆ Public Health
• ☆ Global Health
• ☆ Disease Control And Prevention
• ☆ Quality of Life Assessment
• ☆ Complementary & Alternative Medicine
• ☆ Hypothesis
• ☆ Peer Review
• ☆ Research Methodology
• ☆ Survey Design & Methodology
• ☆ User Research
• ☆ Quantitative User Research
• ☆ Qualitative User Research
• ☆ Meta-Research
• ☆ Feasibility Studies
• ☆ Fact Checking
• ☆ Literature Search
• ☆ Gap Analysis
• ☆ Regulatory Writing
• ☆ Nonclinical Study Documentation
• ☆ Clinical Trial Documentation
• ☆ Clinical Trial Protocol Writing
• ☆ Clinical Study Reports
• ☆ Medical Writing
• ☆ Healthcare Communications
• ☆ Research Summaries & Abstracts
• ☆ Technical & Scientific Writing
• ☆ Manuscript & Journal Article Writing
• ☆ Experimental Protocols
• ☆ SOP & Protocol Writing
• ☆ Case Studies
• ☆ Textbook Content Writing
• ☆ Science Communication
• ☆ Literature Review
• ☆ Traditional/Narrative Literature Review
• ☆ Systematic Literature Review
• ☆ Copywriting
• ☆ Emails & Newsletters
• ☆ User Guides & Handbooks
• ☆ Scientific Proofreading & Editing
• ☆ Proofreading & Editing
• ☆ Language Translation
• ☆ Course Content Writing
• ☆ Grant Writing

サービス

• Writing
• Research
• Consulting
• Data & AI

Writing Clinical Trial Documentation, Medical Writing, Non-Medical Regulatory Writing, Technical Writing, Creative Writing, Audio Transcription, General Proofreading & Editing, Translation

Research Fact Checking, Gray Literature Search, Scientific and Technical Research, Systematic Literature Review, Secondary Data Collection

Consulting Scientific and Technical Consulting

Data & AI Statistical Analysis, Data Visualization

職務経験

MSCA COFUND Postdoctoral Fellow

University of Cyprus (Nicosia, Cyprus)

11月 2023 - 現在

Postdoctoral Fellow

University of Cyprus

11月 2023 - 現在

Postdoctoral Researcher

University of Cyprus (Nicosia, Cyprus)

9月 2021 - 10月 2023

Research Assistant - Research Associate

University of Sheffield (Sheffield, UK)

8月 2020 - 5月 2021

Research Assistant - Research Associate

University of Sheffield (Sheffield, UK)

8月 2019 - 8月 2020

学歴

PhD Molecular Medicine

University of Sheffield (Sheffield, UK)

11月 2016 - 12月 2021

MSc Molecular Medicine

University of Sheffield (Sheffield, UK)

9月 2015 - 1月 2016

BSc Chemistry

Aristotle University of Thessaloniki (Thessaloniki, Greece)

9月 2010 - 3月 2015

認定資格

• Google Data Analytics

  Google (Coursera)

  7月 2025 - 現在

• Data Science for Life Scientists

  EMBL-EBI

  6月 2025 - 現在

• GOOGLE PROMPTING ESSENTIALS

  Google (Coursera)

  1月 2025 - 現在

• ICH Good Clinical Practice E6 (R2)

  The Global Health Network

  12月 2024 - 現在

• ICH Good Clinical Practice E6 (R2)

  The Global Health Network

  8月 2020 - 現在

• Introduction to Good Clinical Laboratory Practice

  The Global Health Network

  8月 2020 - 現在

• Research Integrity - Biomedical Sciences

  EPIGEUM (Sage / SAGE Publishing)

  8月 2017 - 現在

出版物

JOURNAL ARTICLE

Constantinos Deltas, Gregory Papagregoriou, Stavroula F. Louka, Apostolos Malatras, Frances Flinter, Daniel P. Gale, Susie Gear, Oliver Gross, Julia Hoefele, Rachel Lennon, et al. (2023). Genetic Modifiers of Mendelian Monogenic Collagen IV Nephropathies in Humans and Mice . Genes.

Constantinos Deltas, Gregory Papagregoriou, Stavroula F. Louka, Apostolos Malatras, Frances Flinter, Daniel P. Gale, Susie Gear, Oliver Gross, Julia Hoefele, Rachel Lennon, et al. (2023). Genetic Modifiers of Mendelian Monogenic Collagen IV Nephropathies in Humans and Mice . Genes.

Cotton S, McHugh MP, Dewar R, Haas JG, Templeton K, COVID-19 Genomics UK (COG-UK) Consortium(2023). Investigation of hospital discharge cases and SARS-CoV-2 introduction into Lothian care homes . The Journal of hospital infection.

Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, Cantoni D, Scott S, Logan N, Ashraf S, et al.(2022). Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway . Nature microbiology.

Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A, Hosmillo M, Rees-Spear C, Mlcochova P, Lumb IU, et al.(2022). Author Correction: SARS-CoV-2 evolution during treatment of chronic infection . Nature.

Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP, Walls AC, Kemp SA, Bassi J, Pinto D, Silacci-Fregni C, et al.(2022). Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies . Nature.

Parker MD, Stewart H, Shehata OM, Lindsey BB, Shah DR, Hsu S, Keeley AJ, Partridge DG, Leary S, Cope A, et al.(2022). Altered subgenomic RNA abundance provides unique insight into SARS-CoV-2 B.1.1.7/Alpha variant infections . Communications biology.

Nickbakhsh S, Hughes J, Christofidis N, Griffiths E, Shaaban S, Enright J, Smollett K, Nomikou K, Palmalux N, Tong L, et al.(2022). Genomic epidemiology of SARS-CoV-2 in a university outbreak setting and implications for public health planning . Scientific reports.

Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, Cantoni D, Scott S, Logan N, Ashraf S, et al.(2022). SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway . Nature microbiology.

Eales O, Page AJ, de Oliveira Martins L, Wang H, Bodinier B, Haw D, Jonnerby J, Atchison C, COVID-19 Genomics UK (COG-UK) Consortium, Ashby D, et al.(2022). SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2 . BMC infectious diseases.

Kläser K, Molteni E, Graham M, Canas LS, Österdahl MF, Antonelli M, Chen L, Deng J, Murray B, Kerfoot E, et al.(2022). COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study . Scientific reports.

Vöhringer HS, Sanderson T, Sinnott M, De Maio N, Nguyen T, Goater R, Schwach F, Harrison I, Hellewell J, Ariani CV, et al.(2022). Publisher Correction: Genomic reconstruction of the SARS CoV-2 epidemic in England . Nature.

Lindsey BB, Villabona-Arenas CJ, Campbell F, Keeley AJ, Parker MD, Shah DR, Parsons H, Zhang P, Kakkar N, Gallis M, et al.(2022). Characterising within-hospitalSARS-CoV-2 transmission events using epidemiological and viral genomic data across two pandemic waves . Nature communications.

Snell LB, Wang W, Alcolea-Medina A, Charalampous T, Batra R, de Jongh L, Higgins F, Nebbia G, COG-UK HOCI Investigators, Wang Y, et al.(2022). Descriptive comparison of admission characteristics between pandemic waves and multivariable analysis of the association of the Alpha variant (B.1.1.7 lineage) of SARS-CoV-2 with disease severity in inner London . BMJ open.

Aggarwal D, Page AJ, Schaefer U, Savva GM, Myers R, Volz E, Ellaby N, Platt S, Groves N, Gallagher E, et al.(2022). Genomic assessment of quarantine measures to prevent SARS-CoV-2 importation and transmission . Nature communications.

Aggarwal D, Warne B, Jahun AS, Hamilton WL, Fieldman T, du Plessis L, Hill V, Blane B, Watkins E, Wright E, et al.(2022). Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission . Nature communications.

Lindsey BB, Villabona-Arenas CJ, Campbell F, Keeley AJ, Parker MD, Shah DR, Parsons H, Zhang P, Kakkar N, Gallis M, et al.(2022). Publisher Correction: Characterising within-hospital SARS-CoV-2 transmission events using epidemiological and viral genomic data across two pandemic waves . Nature communications.

Vöhringer HS, Sanderson T, Sinnott M, De Maio N, Nguyen T, Goater R, Schwach F, Harrison I, Hellewell J, Ariani CV, et al.(2021). Genomic reconstruction of the SARS-CoV-2 epidemic in England . Nature.

de Silva TI, Liu G, Lindsey BB, Dong D, Moore SC, Hsu NS, Shah D, Wellington D, Mentzer AJ, Angyal A, et al.(2021). The impact of viral mutations on recognition by SARS-CoV-2 specific T cells . iScience.

Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, Seaman SR, Harris RJ, Hope R, Lopez-Bernal J, et al.(2021). Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study . The Lancet. Infectious diseases.

Meng B, Kemp SA, Papa G, Datir R, Ferreira IATM, Marelli S, Harvey WT, Lytras S, Mohamed A, Gallo G, et al.(2021). Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7 . Cell reports.

Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, Kläser K, Canas LS, Molteni E, Modat M, et al.(2021). Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study . The Lancet. Public health.

Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon DJ, Dabrera G, O'Toole Á, et al.(2021). Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England . Nature.

Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP, Walls AC, Kemp SA, Bassi J, Pinto D, Silacci-Fregni C, et al.(2021). Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies . Nature.

Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A, Hosmillo M, Rees-Spear C, Mlcochova P, Lumb IU, et al.(2021). SARS-CoV-2 evolution during treatment of chronic infection . Nature.

PREPRINT

Lindsey BB, Villabona-Arenas CJ, Campbell F, Keeley AJ, Parker MD, Shah DR, Parsons H, Zhang P, Kakkar N, Gallis M, et al.(2021). Characterising within-hospital SARS-CoV-2 transmission events: a retrospective analysis integrating epidemiological and viral genomic data from a UK tertiary care setting across two pandemic waves .

Parker MD, Lindsey BB, Shah DR, Hsu S, Keeley AJ, Partridge DG, Leary S, Cope A, State A, Johnson K, et al.(2021). Altered Subgenomic RNA Expression in SARS-CoV-2 B.1.1.7 Infections .